Sarabia-Vallejo Álvaro, Caja María Del Mar, Olives Ana I, Martín M Antonia, Menéndez J Carlos
Unidad de Química Orgánica y Farmacéutica, Departamento de Química en Ciencias Farmacéuticas, Facultad de Farmacia, Universidad Complutense, 28040 Madrid, Spain.
Unidad de Química Analítica, Departamento de Química en Ciencias Farmacéuticas, Facultad de Farmacia, Universidad Complutense, 28040 Madrid, Spain.
Pharmaceutics. 2023 Sep 19;15(9):2345. doi: 10.3390/pharmaceutics15092345.
Many active pharmaceutical ingredients show low oral bioavailability due to factors such as poor solubility and physical and chemical instability. The formation of inclusion complexes with cyclodextrins, as well as cyclodextrin-based polymers, nanosponges, and nanofibers, is a valuable tool to improve the oral bioavailability of many drugs. The microencapsulation process modifies key properties of the included drugs including volatility, dissolution rate, bioavailability, and bioactivity. In this context, we present relevant examples of the stabilization of labile drugs through the encapsulation in cyclodextrins. The formation of inclusion complexes with drugs belonging to class IV in the biopharmaceutical classification system as an effective solution to increase their bioavailability is also discussed. The stabilization and improvement in nutraceuticals used as food supplements, which often have low intestinal absorption due to their poor solubility, is also considered. Cyclodextrin-based nanofibers, which are polymer-free and can be generated using environmentally friendly technologies, lead to dramatic bioavailability enhancements. The synthesis of chemically modified cyclodextrins, polymers, and nanosponges based on cyclodextrins is discussed. Analytical techniques that allow the characterization and verification of the formation of true inclusion complexes are also considered, taking into account the differences in the procedures for the formation of inclusion complexes in solution and in the solid state.
许多活性药物成分由于溶解度差、物理和化学不稳定性等因素,口服生物利用度较低。与环糊精以及基于环糊精的聚合物、纳米海绵和纳米纤维形成包合物,是提高许多药物口服生物利用度的一种有效手段。微囊化过程会改变被包封药物的关键性质,包括挥发性、溶解速率、生物利用度和生物活性。在此背景下,我们展示了通过将不稳定药物包封于环糊精中来实现其稳定化的相关实例。还讨论了与生物药剂学分类系统中IV类药物形成包合物作为提高其生物利用度的有效解决方案。同时也考虑了用作食品补充剂的营养保健品的稳定化和改进,这些营养保健品由于溶解度差,肠道吸收往往较低。基于环糊精的纳米纤维不含聚合物,可采用环境友好型技术制备,能显著提高生物利用度。本文还讨论了基于环糊精的化学修饰环糊精、聚合物和纳米海绵的合成。考虑到溶液和固态中包合物形成过程的差异,还探讨了能够表征和验证真正包合物形成的分析技术。